3 No-Brainer Dividend Stocks to Buy in September
When's a good time to invest in dividend stocks? Any month that has a vowel in its name.
We asked three Motley Fool contributors to identify no-brainer dividend stocks to buy in September. Here's why they picked (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD).
Keith Speights (AbbVie): It's never easy for a drugmaker to lose patent exclusivity for its top-selling product. AbbVie is certainly feeling the pain now that Humira faces biosimilar competition in the U.S. The company's revenue, profits, and share price have fallen.
Source Fool.com
AbbVie Inc. Aktie
169,80 €
0,89 %
Überwältigende Zustimmung für AbbVie Inc. mit ausschließlich Buy-Einschätzungen.
Ein positives, wenn auch bescheidenes, Potenzial für AbbVie Inc. mit einem Kursziel von 180 € im Vergleich zum aktuellen Kurs von 169.8 €.
